Topiramate does not alter the kinetics of arachidonic or docosahexaenoic acid in brain phospholipids of the unanesthetized rat

Neurochemical Research

Volumn 30, Issue 5, 2005, Pages 677-683

  Lee, Ho Joo ^a   Ghelardoni, Sandra ^a   Chang, Lisa ^a   Bosetti, Francesca ^a   Rapoport, Stanley I ^a   Bazinet, Richard P ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Anti epileptic; Arachidonic acid; Bipolar disorder; Brain; Kinetics; Lithium; Mania; Metabolism; Mood stabilizer; Topiramate; Turnover

Indexed keywords

ACYL COENZYME A; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; PHOSPHOLIPID; TOPIRAMATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMORAL ARTERY; MALE; NONHUMAN; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; RAT;

ANIMALS; ARACHIDONIC ACID; BRAIN; DOCOSAHEXAENOIC ACIDS; FRUCTOSE; KINETICS; MALE; PHOSPHOLIPIDS; RATS; RATS, INBRED F344;

EID: 23944497635     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-005-2756-3     Document Type: Article

References (50)

1. E. Ben-Menachem O. Henriksen M. Dam M. Mikkelsen D. Schmidt S. Reid R. Reife L. Kramer G Pledger R. Karim 1996 Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures Epilepsia 37 539 543
2. M. Privitera R. Fincham J. Penry R. Reife L. Kramer G. Pledger R. Karim 1996 Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group Neurology 46 1678 1683
3. E. Faught B. J. Wilder R. E. Ramsay R. A. Reife L. D. Kramer G. W. Pledger R. M. Karim 1996 Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group Neurology 46 1684 1690
4. C. A. Tassinari R. Michelucci P. Chauvel J. Chodkiewicz S. Shorvon O. Henriksen M. Dam R. Reife G. Pledger R. Karim 1996 Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy Epilepsia 37 763 768
5. V. Biton G. D. Montouris F. Ritter J. J. Riviello R. Reife P. Lim G. Pledger 1999 A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group Neurology 52 1330 1337
6. J. L. Brandes J. R. Saper M. Diamond J. R. Couch D. W. Lewis J. Schmitt W. Neto S. Schwabe D. Jacobs 2004 Topiramate for migraine prevention: A randomized controlled trial JAMA 291 965 973
7. E. Vieta J. Sanchez-Moreno J. M. Goikolea C. Torrent A. Benabarre F. Colom A. Martinez-Aran M. Reinares M. Comes B. Corbella 2003 Adjunctive topiramate in bipolar II disorder World J. Biol. Psychiatry 4 172 176
8. E. Vieta J. M. Goikolea J. M. Olivares A. Gonzalez-Pinto A. Rodriguez F. Colom M. Comes C. Torrent J. Sanchez-Moreno 2003 1-year follow-up of patients treated with risperidone and topiramate for a manic episode J. Clin. Psychiatry 64 834 839
9. D. Marcotte 1998 Use of topiramate, a new anti-epileptic as a mood stabilizer J. Affect. Disord. 50 245 251
10. J. R. Calabrese P. E. Keck Jr. S. L. McElroy M. D. Shelton 2001 A pilot study of topiramate as monotherapy in the treatment of acute mania J. Clin. Psychopharmacol. 21 340 342
11. S. L. McElroy T. Suppes P. E. Keck M. A. Frye K. D. Denicoff L. L. Altshuler E. S. Brown W. A. Nolen R. W. Kupka J. Rochussen G. S. Leverich R. M. Post 2000 Open-label adjunctive topiramate in the treatment of bipolar disorders Biol. Psychiatry 47 1025 1033
12. C. F. Poulsen T. A. Simeone T. E. Maar V. Smith-Swintosky H. S. White A. Schousboe 2004 Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons Neurochem. Res. 29 275 282
13. M. Angehagen E. Ben-Menachem R. Shank L. Ronnback E. Hansson 2004 Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level J. Neurochem. 88 320 325
14. M. Angehagen E. Ben-Menachem L. Ronnback E. Hansson 2003 Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal-astroglial cultures Epilepsy Res. 54 63 71
15. D. S. Gryder M. A. Rogawski 2003 Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons J. Neurosci. 23 7069 7074
16. S. S. Jahromi M. R. Pelletier P. J. McDonald H. Khosravani P. L. Carlen 2000 Antiepileptic efficacy of topiramate: assessment in two in vitro seizure models Brain Res. 872 20 28
17. J. W. Gibbs 3rd S. Sombati R. J. DeLorenzo D. A. Coulter 2000 Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons Epilepsia 41 Suppl 1 S10 S16
18. R. M. Kaminski M. Banerjee M. A. Rogawski 2004 Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist Neuropharmacology 46 1097 1104
19. S. I. Rapoport F. Bosetti 2002 Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry 59 592 596
20. G. Y. Sun J. Xu M. D. Jensen A. Simonyi 2004 Phospholipase A2 in the central nervous system: Implications for neurodegenerative diseases J. Lipid Res. 45 205 213
21. P. J. Robinson J. Noronha J. J. DeGeorge L. M. Freed T. Nariai S. I. Rapoport 1992 A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: Review and critical analysis Brain Res. Brain Res. Rev. 17 187 214
22. 14C) arachidonate to examine regional brain lipid metabolism in unanesthetized rats J. Neurosci. Res. 24 413 423
23. S. C. Cunnane M. A. Ryan C. R. Nadeau R. P. Bazinet K. Musa-Veloso U. McCloy 2003 Why is carbon from some polyunsaturates extensively recycled into lipid synthesis? Lipids 38 477 484
24. M. C. Chang E. Grange O. Rabin J. M. Bell D. D. Allen S. I. Rapoport 1996 Lithium decreases turnover of arachidonate in several brain phospholipids Neurosci. Lett. 220 171 174
25. Lee, H., Rao, J., Chang, L., Rapoport, S., and Bazinet R. 2004. The effects of chronic carbamazepine, an antibipolar disorder drug, on the turnover of arachidonic and docosahexaenoic acids in brain phospholipids of the awake rat. Soc. Neurosci.
26. M. C. Chang M. A. Contreras T. A. Rosenberger J. J. Rintala J. M. Bell S. I. Rapoport 2001 Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers J. Neurochem. 77 796 803
27. M. C. Chang J. M. Bell A. D. Purdon E. G. Chikhale E. Grange 1999 Dynamics of docosahexaenoic acid metabolism in the central nervous system: Lack of effect of chronic lithium treatment Neurochem Res. 24 399 406
28. S. Ghelardoni Y. A. Tomita J. M. Bell S. I. Rapoport F. Bosetti 2004 Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain Biol. Psychiatry 56 248 254
29. J. Rintala R. Seemann K. Chandrasekaran T. A. Rosenberger L. Chang M. A. Contreras S. I. Rapoport M. C. Chang 1999 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain Neuroreport 10 3887 3890
30. G. R. Weerasinghe R. Seemann S. I. Rapoport F. Bosetti 2003 Lithium chloride, administered chronically to rats, does not affect the fractional phosphorylation of brain cytosolic phospholipase A2, while reducing its net protein level Brain Res. Bull. 59 303 306
31. F. Bosetti J. Rintala R. Seemann T. A. Rosenberger M. A. Contreras S. I. Rapoport M. C. Chang 2002 Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain Mol. Psychiatry 7 845 850
32. F. Bosetti G. R. Weerasinghe T. A. Rosenberger S. I. Rapoport 2003 Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain J. Neurochem. 85 690 696
33. Bazinet, R., Rao, J., Chang, L., Rapoport, S. I., and Lee, H. 2005. Chronic Valproate Does Not Alter The Kinetics Of Docosahexaenoic Acid Within Brain Phospholipids Of The Unanesthetized Rat. Psychopharmacology (Berl). In Press.
34. Ghelardoni, S., Bazinet, R., Rapoport, S., and Bosetti, F. 2004. Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism. Psychopharmacology, In Press.
35. D. A. York L. Singer S. Thomas G. A. Bray 2000 Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs Nutrition 16 967 975
36. A. Shaldubina H. Einat H. Szechtman H. Shimon R. H Belmaker 2002 Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder J. Neural Transm. 109 433 440
37. S. I. Rapoport M. C. Chang A. A. Spector 2001 Delivery and turnover of plasma-derived essential PUFAs in mammalian brain J. Lipid Res. 42 678 685
38. BipolarNews org. (2004) Research News. Topiramate in bipolar disorder. 2004.
39. Sachs G., Kushner S., Wang D., Olson W., Capece J., Fazzio L., N, R. (2004) Topiramate in adults with acute bipolar I mania: Pooled results. American Psychiatric Association Annual Meeting. NR365.
40. G. S. Sachs 2003 Decision tree for the treatment of bipolar disorder J. Clin. Psychiatry. 64 Suppl 8 35 40
41. L. N. Yatham 2004 Newer anticonvulsants in the treatment of bipolar disorder J. Clin. Psychiatry 65 Suppl 10 28 35
42. J. Deutsch S. I. Rapoport A. D. Purdon 1997 Relation between free fatty acid and acyl-CoA concentrations in rat brain following decapitation Neurochem. Res. 22 759 765
43. V. P. Skipski J. J. Good M. Barclay R. B. Reggio 1968 Quantitative analysis of simple lipid classes by thin-layer chromatography Biochim. Biophys. Acta 152 10 19
44. M. Makrides M. A. Neumann R. W. Byard K. Simmer R. A. Gibson 1994 Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants Am. J. Clin. Nutr. 60 189 194
45. J. Deutsch E. Grange S. I. Rapoport A. D. Purdon 1994 Isolation and quantitation of long-chain acyl-coenzyme A esters in brain tissue by solid-phase extraction Anal. Biochem. 220 321 323
46. E. Grange J. Deutsch Q. R. Smith M. Chang S. I. Rapoport A. D. Purdon 1995 Specific activity of brain palmitoyl-CoA pool provides rates of incorporation of palmitate in brain phospholipids in awake rats J. Neurochem. 65 2290 2298
47. A. L. Stoll W. E. Severus M. P. Freeman S. Rueter H. A. Zboyan E. Diamond K. K. Cress L. B. Marangell 1999 Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial Arch. Gen. Psychiatry 56 407 412
48. M. A. Contreras M. C. Chang T. A. Rosenberger R. S. Greiner C. S. Myers N. Salem Jr. S. I. Rapoport 2001 Chronic nutritional deprivation of n-3 alpha-linolenic acid does not affect n-6 arachidonic acid recycling within brain phospholipids of awake rats J. Neurochem. 79 1090 1099
49. M. A. Contreras S. I. Rapoport 2002 Recent studies on interactions between n-3 and n-6 polyunsaturated fatty acids in brain and other tissues Curr. Opin. Lipidol. 13 267 272
50. R. P. Bazinet H. Douglas S. C. Cunnane 2003 Whole-body utilization of n-3 PUFA in n-6 PUFA-deficient rats Lipids 38 187 189